AVANTGEN
Premier Partner in Advancing Antibody Drugs
Premier Partner in Advancing Antibody Drugs
AVANTGEN is a renowned biotechnology company founded in 2006 and based in San Diego, United States. The company's slogan "Premier Partner in Advancing Antibody Drugs" encapsulates its dedication to accelerating antibody-based therapeutics for their scientific partners through innovative platforms. AvantGen's primary focus lies in the biotechnology and healthcare industries.
The latest notable investment in AvantGen occurred on 25 May 2021, in the form of a grant investment from the National Institutes of Health. This injection of funds is a testament to the recognition and support the company is receiving for its pioneering work in the field of antibody-based therapeutics.
AvantGen's collaborative and driven team is steadfast in their pursuit, embodying a fun yet focused approach towards advancing antibody drugs. With its track record and commitment, AvantGen stands as a promising venture in the biotechnology sector, drawing attention from potential investors and partners alike.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | Unknown | 1 | National Institutes of Health | 25 May 2021 |
| Grant | Unknown | 1 |
-logo.jpg){kind=logo}
|
01 Mar 2015 |
No recent news or press coverage available for AVANTGEN.
We care about your data, and we'd love to use cookies make your experience better.
